Granted Patent
B2
US 8,557,803 · App. 13/833,520 · Granted Oct 15, 2013
Purinone derivative
Assignee:
Ono Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
Claims (2)
1. 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a salt thereof.
2. 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one.
Priority Claims (1)
JP 2010-123727
· May 31, 2010
· national
Continuity (2)
Continuation
13700774